Axoft’s Fleuron™ material is up to 10,000x softer than the polyimide used in existing brain implant devices and has been used in an in-human study at The Panama Clinic. Many iBCIs struggle to maintain ...

Axoft demonstrated the safety and functionality of its novel Fleuron™ material in the operating room, which was also featured in new research that outlines the technology’s clinical applications, and ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axoft, a neurotechnology company, today announced the approval of its first-in-human clinical study, which will take place in early 2025 at The Panama Clinic. The ...

Alex Knapp is a Forbes senior editor covering healthcare and science. Paul Le Floch’s company, Axoft, is developing brain implants made from soft, flexible materials that reduce injury and could treat ...

Massachusetts-based Axoft has conducted its first disclosed brain implant trials in China, testing its flexible 'Fleuron' device on four patients in Shanghai. The move marks a rare instance of ...

Powered by the company’s novel Fleuron™ material, Axoft’s iBCI platform enables unprecedented biocompatibility and high quality neural data capture with successful implantation in 11 patients to date.

With the completion of a $55m fundraise, Axoft is planning to advance the development of its implantable brain-computer interfaces (iBCI). The Massachusetts-based company’s oversubscribed Series A ...

Rosatom will cooperate with Axoft in the field of integrated import substitution. Greenatom Simple Solutions has signed a distribution agreement with Axoft. This will allow Axoft partners and their ...

Axoft and MTS RED have signed a cooperation agreement. Axoft will supply in Russia a platform for managing secure development of MTS RED ASOC software, a system for improving cyber literacy of ...

Axoft’s novel Fleuron™ material is up to 10,000x softer than the polyimide used in existing brain implants. It offers superior biocompatibility, reduces tissue scarring and lead migration, and ...